The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions

References

• Agnihotri SM, Vavia PR. 2009. Diclofenac-loaded biopolimeric nanosuspensions for ophthalmic application. Nanomed Nanotechnol. 5(1):90–95.
   PubMed Web of Science ®Google Scholar
• Al Shaal L, Müller RH, Keck CM. 2010. Preserving hesperetin nanosuspensions for dermal application. Pharmazie. 65(2):86–92.
   PubMed Web of Science ®Google Scholar
• Beirowski J, Inghelbrecht S, Arien A, Gieseler H. 2011. Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J Pharm Sci. 100(5):1958–1968.
   PubMed Web of Science ®Google Scholar
• Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. 2009. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 8:6–6.
   PubMed Web of Science ®Google Scholar
• Chen H, Khemtong C, Yang X, Chang X, Gao J. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 16(7–8):354–360.
   PubMed Web of Science ®Google Scholar
• Dillen K, Vandervoort J, Mooter GV, Verheyden L, Ludwig A. 2004. Factoriel design, physicochemical characterization and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm. 275(1–2):171–187.
   PubMed Web of Science ®Google Scholar
• Eerdenbrugh BV, Mooter GV, Augustijns P. 2008. Top-down production of drug nanocrystals: nanosuspension stabilization miniaturization and transformation into solid products. Int J Pharm. 364:64–75.
   PubMed Web of Science ®Google Scholar
• Elsayed I, Abdelbary AA, Elshafeey AH. 2014. Nanosizing of a poorly soluble drug: technique optimization, factorial analysis, and pharmacokinetic study in healty human volunteers. Int J Nanomed. 9:2943–2953.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Zheng T, Wang S. 2007. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Indust Pharm. 33(12):1332–1339.
   PubMed Web of Science ®Google Scholar
• García-Millán E, Quintáns-Carballo M, Otero-Espinar FJ. 2017. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions. Int J Pharm. 525(1):226–236.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Schenck D, Bose S, Ruegger C. 2012. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption. European J Pharm Sci. 47(4):718–728.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Michniak-Kohn B. 2013. Influence of critical parameters of nanosuspension formulation on the permeability of a poorly soluble drug through the skin—A case study. AAPS PharmSciTech. 14(3):1108–1117.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, Garcia ML. 2011. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology. 22(4):045101.
   PubMed Web of Science ®Google Scholar
• Han F, Yin R, Che X, Yuan J, Cui Y, Yin H, Li S. 2012. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 439(1–2):349–357.
   PubMed Web of Science ®Google Scholar
• Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y. 2014. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. Int J Pharm. 477(1–2):251–260.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Kayser O, Müller RH. 2000. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarapezide. Int J Pharm. 196(2):161–164.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Müller RH. 2002. Production and characterization of a budenoside nanosuspension for pulmonary administration. Pharm Res. 19(2):189–194.
   PubMed Web of Science ®Google Scholar
• Krause KP, Müller RH. 2001. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenization. Int J Pharm. 214(1–2):21–24.
   PubMedGoogle Scholar
• Li Y, Zhao X, Zu Y, Zhang Y. 2015. Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization. Int J Pharm. 490(1–2):324–333.
   PubMedGoogle Scholar
• Müller RH, Böhm BHL, Grau MJ. 2000. Nanosuspensions—a formulation approach for poorly soluble and poorly bioavailable drugs. In Handbook of pharmaceutical controlled release technology. p. 345–357.
   Google Scholar
• Müller RH, Gohla S, Keck CM. 2011. State of the art nanocrystals- special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 78(1):1–9.
   PubMed Web of Science ®Google Scholar
• Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. 2018. Dermal flurbiprofen nanosuspensions: optimization with design of experiment approach and in vitro evaluation. Eur J Pharm Sci. 122:254–263.
   PubMed Web of Science ®Google Scholar
• Parmar K, Patel J, Sheth N. 2015. Formulation and optimization of embelin nanosuspensions using central composite design for dissolution enhancement. J Del Sci Tech. 29:1–7.
   Web of Science ®Google Scholar
• Pelikh O, Stahr P-L, Huang J, Gerst M, Scholz P, Dietrich H, Geisel N, Keck CM. 2018. Nanocrystals for improved dermal drug delivery. Eur J Pharm Biopharm. 128:170–178.
   PubMed Web of Science ®Google Scholar
• Petersen R. 2006. Nanocrystals for use in topical cosmetic formulations and method of production thereof. United States patent US 60/8866233.
   Google Scholar
• Pyo SM, Hespelera D, Keck CM, Müller RH. 2017. Dermal miconazole nitrate nanocrystals – formulation development, increased antifungal efficacy & skin penetration. Int J Pharm. 531:350–359.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 3(9):785–796.
   PubMed Web of Science ®Google Scholar
• Radvan MA, Aboul-Enein HY. 2004. In vitro release and stereoselective disposition of Flurbiprofen loaded to poly (D,L-lactide-co-glicolide) nanoparticles in rats. Chirality. 16:119–125.
   PubMed Web of Science ®Google Scholar
• Sajeev C, Jadhav PR, RaviShankar D, Saha RN. 2002. Determination of flurbiprofen in pharmaceutical formulations by UV spectrophotometry and liquid chromatography. Anal Chim Acta. 463(2):207–217.
   Web of Science ®Google Scholar
• Shegokar R, Müller RH. 2010. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 399(1–2):129–139.
   PubMed Web of Science ®Google Scholar
• Supuk E, Ghori MU, Addo KA, Laity PR, Panchmatia PM, Conway BR. 2013. The influence of salt formation on electrostatic and compression properties of flurbiprofen salts. Int J Pharm. 458:118–127.
   PubMed Web of Science ®Google Scholar
• Tuomela A, Hirvonen J, Peltonen L. 2016. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 8:16.
   Google Scholar
• Van Eerdenburgh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, Van den Mooter G. 2009. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci. 98:2091–2103.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Lippacher A, Müller RH. 2001. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Contr Rel. 128:134–141.
   Google Scholar
• Zhai X, Lademann J, Keck CM, Müller RH. 2014. Nanocrystals of medium soluble actives-novel concept for improved dermal delivery and production strategy. Int J Pharm. 470(1–2):141–150.
   PubMed Web of Science ®Google Scholar